Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination

Llaneras, Jordi; Ruiz-Cobo, Juan Carlos; Rando-Segura, Ariadna; Barreira-Díaz, Ana; Domínguez-Hernández, Raquel; Rodríguez-Frías, Francisco; Campins, Magda; Colom, Joan; Casado, Miguel Angel; Blanco-Grau, Albert; Bañares, Juan; Monforte, Arnau; Falcó-Roget, Anna; Ruíz, Lourdes; Meza, Beatriz; Pumarola, Tomàs; Riveiro-Barciela, Mar; Esteban, Rafael; Buti, María

doi:10.1016/j.jhepr.2023.100932

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Individuals with no history of HBV infection and no previous immunity are vaccinated, and infected individuals are evaluated for therapy. Another example is hospital emergency room screening, which has shown a higher prevalence of hepatitis B infection than in the general population and facilitates seamless linkage to care 20 . Again, important steps in this line are the generation of robust epidemiological data to guide HBV elimination strategies and a strong political commitment to provide specific funding.…”

Section: Potential Solutionsmentioning

confidence: 99%

HBV elimination in Europe: Current status and challenges

Buti,

Duffell

2024

Clinical Liver Disease

View full text Add to dashboard Cite

In 2016, an estimated 3.6 million people were living with chronic HBV infection in the 30 countries of the European Union (EU) and European Economic Area (EEA). Together with HCV infection, HBV is responsible for ~55% of all deaths related to liver cancer and 45% of deaths due to cirrhosis and other chronic liver conditions. Notably, deaths from HCC continue to increase, with hepatitis-specific deaths in the EU exceeding those attributed to either tuberculosis or HIV. [1,2] The epidemiological status of HBV infection in EU/EEA countries exhibits marked geographical differences and varying burdens of disease among key affected groups, such as men who have sex with men, people who inject drugs (PWID), and some migrant populations. [3] The prevalence of HBV is low in most EU/EEA countries with the virus affecting <0.1% of the population, especially among countries in the North West part of the region where a high proportion of cases are reported among migrants from countries with a higher endemicity and incomplete vaccination programs. [3] Nonetheless, a recent systematic review of HBV prevalence across EU/EEA countries found studies with prevalence estimates up to 8% among key risk groups such as specific migrant populations (eg, refugees) and people in prison. However, prevalence among most population groups has actually decreased in line with changes in prevalence among the general population, which reflects the impact of highly effective vaccination programs.

show abstract

Section: Potential Solutionsmentioning

confidence: 99%

HBV elimination in Europe: Current status and challenges

Buti,

Duffell

2024

Clinical Liver Disease

View full text Add to dashboard Cite

show abstract

“…It is with a great interest that we read the article by Llaneras et al. , 1 highlighting the role of the emergency department as a main healthcare gateway for HBV screening. HBV infection remains a significant global health problem and an important cause of cirrhosis, liver failure, and especially hepatocellular carcinoma.…”

mentioning

confidence: 99%

Time to broaden the screening strategy for chronic hepatitis B virus infection beyond the emergency department

Kalo,

Baig,

Read

et al. 2024

JHEP Reports

View full text Add to dashboard Cite

Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years

Torre,

Festa,

Sarcina

et al. 2024

Viruses

View full text Add to dashboard Cite

Hepatitis C is a disease for which in approximately 30 years we have gone from the discovery of the causative agent in 1989, to the introduction of direct-acting antiviral (DAAs) therapies starting from 2011, and to a proposal for its elimination in 2016, with some countries being on track for this goal. Elimination efforts, in the absence of a vaccine, rely on prevention measures and antiviral therapies. However, treatment rates have declined in recent years and are not considered adequate to achieve this goal at a global level. This poses a great epidemiological challenge, as HCV in many countries still causes a significant burden and most infected people are not yet diagnosed. Consequently, efforts are needed at different levels with common purposes: to facilitate access to screening and diagnosis and to improve linkage to care pathways. In this review, we discuss the latest epidemiological findings on HCV infection, the obstacles to its elimination, and strategies that are believed to be useful to overcome these obstacles but are applied unevenly across the world.

show abstract

Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination

Cited by 3 publications

References 22 publications

HBV elimination in Europe: Current status and challenges

HBV elimination in Europe: Current status and challenges

Time to broaden the screening strategy for chronic hepatitis B virus infection beyond the emergency department

Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years

Contact Info

Product

Resources

About